Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Mereo Biopharma
Thumbnail
May 11, 2022

Looking beyond Roche’s Tigit bombshell

The failure of Skyscraper-01 calls into question Roche’s vast investment in Tigit blockade, but is there broader significance?

Thumbnail
May 09, 2022

Asset resuscitation fails to resuscitate Mereo

Mereo claims another success with a big pharma castoff, but its win in alpha 1-antitrypsin deficiency is questionable.

Article image
Vantage logo
December 31, 2021

Covid-19 developments over the Christmas period

Drug makers and regulators take aim at Omicron.

Article image
Vantage logo
December 20, 2021

Another failure heaps more pressure on Novartis

Deals will come into even greater focus after the failure of ligelizumab, one of the group’s brightest pipeline hopes.

Article image
Vantage logo
November 12, 2021

Astra presses on with bispecifics

Followers of novel immuno-oncology mechanisms will note Astrazeneca as a new player in Tigit and Tim3.

Article image
Vantage logo
November 02, 2021

Centessa claims a place in the antitrypsin deficiency pipeline

But investors will need more convincing; and others are more advanced, with Arrowhead and Inhibrx ones to watch.

Article image
Vantage logo
September 29, 2021

Crucial clinical events for the smaller players

Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.

Article image
Vantage logo
June 14, 2021

Glaxo pays handsomely to join the Tigit chase

Article image
Vantage logo
June 10, 2021

Arcus nears crunch time for Gilead opt-in

The anti-Tigit MAb domvanalimab will generate key clinical results any day; will they be good enough for Gilead to opt in?

Article image
Vantage logo
May 18, 2021

Latest stage of Tigit mania nets Agenus $200m

Article image
Vantage logo
April 15, 2021

Vertex’s second try at a rare lung disorder

A small molecule for alpha-1 antitrypsin deficiency faces a key clinical test, and its chances of success aren’t good.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.